SPIRE-2 (Klaar)
The Evaluation of Bococizumab (PF-04950615) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2)
- Middel
- Bococizumab
- Populatie
- ASCVD
- Fase
- III
- Jaar aanvang
- 2014
- Meer informatie
- ClinicalTrials.gov